Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Xeris Biopharma Holdings (XERS) Return on Sales (2021 - 2025)

Historic Return on Sales for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to 0.01%.

  • Xeris Biopharma Holdings' Return on Sales rose 3000.0% to 0.01% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.06%, marking a year-over-year increase of 2800.0%. This contributed to the annual value of 0.27% for FY2024, which is 1100.0% up from last year.
  • Latest data reveals that Xeris Biopharma Holdings reported Return on Sales of 0.01% as of Q3 2025, which was up 3000.0% from 0.03% recorded in Q2 2025.
  • In the past 5 years, Xeris Biopharma Holdings' Return on Sales ranged from a high of 0.01% in Q3 2025 and a low of 3.09% during Q2 2021
  • Moreover, its 5-year median value for Return on Sales was 0.47% (2024), whereas its average is 0.88%.
  • Its Return on Sales has fluctuated over the past 5 years, first tumbled by -6500bps in 2021, then soared by 20500bps in 2022.
  • Quarter analysis of 5 years shows Xeris Biopharma Holdings' Return on Sales stood at 2.37% in 2021, then skyrocketed by 84bps to 0.39% in 2022, then rose by 23bps to 0.3% in 2023, then skyrocketed by 72bps to 0.09% in 2024, then surged by 110bps to 0.01% in 2025.
  • Its last three reported values are 0.01% in Q3 2025, 0.03% for Q2 2025, and 0.15% during Q1 2025.